The efficacy, safety and tolerability of canakinumab in the treatment of familial Mediterranean fever : a systematic review of the literatureKačar, Mark (Avtor) Savic, Sinisa (Avtor) van der Hilst, Jeroen CH (Avtor) familial Mediterranean fever -- therapy -- reviewmonoclonal antibodiescanakinumabanti-IL1 therapyFamilial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%-10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1[beta], has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.Dove Press20202021-04-08 14:43:47Neznano13873UDK: 577.2ISSN pri članku: 1178-7031DOI: 10.2147/JIR.S206204COBISS_ID: 58075139sl© 2020 Kacar et al.